NCT06631053 is a NA clinical trial of velocity-based FIT (VBFIT) in Muscle Atrophy, sponsored by Lance Bollinger.

Who is sponsoring NCT06631053?

NCT06631053 is sponsored by Lance Bollinger.

What drugs are being tested in NCT06631053?

Interventions in NCT06631053: velocity-based FIT (VBFIT), No Exercise.

What condition does NCT06631053 study?

NCT06631053 studies Muscle Atrophy, Muscle Weakness.

Is NCT06631053 still recruiting?

NCT06631053 is currently recruiting now. Last updated 24 October 2025.

Last reviewed 2025-10-24 · How we verify

NCT06631053

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FIT Exercise in 30d of ULLS-induced Muscle Disuse

Recruiting now NA Last updated 24 October 2025

What this trial tests

NA trial testing velocity-based FIT (VBFIT) in Muscle Atrophy in 16 participants. Currently enrolling.

Timeline

23 October 2024

Primary endpoint
1 September 2026

1 September 2026

Quick facts

Lead sponsor	Lance Bollinger
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	23 October 2024
Primary completion	1 September 2026
Estimated completion	1 September 2026
Sites	1 location across United States

Drugs / interventions tested

velocity-based FIT (VBFIT)
No Exercise

Conditions studied

Muscle Atrophy — all drugs for Muscle Atrophy →
Muscle Weakness — all drugs for Muscle Weakness →

Sponsor

Lance Bollinger

Who can join

Adults 35 to 45, any sex, with Muscle Atrophy or Muscle Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine how flywheel-based inertial training (FIT) implemented according to principles of velocity-based training (VBT) and High-Intensity Interval Training (HIIT) affects disuse-induced physical de-conditioning including loss of voluntary muscle strength, aerobic capacity, and balance regulation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Muscle Atrophy

Currently open trials in the same condition.

NCT06253104 — Changes in Skeletal Muscle Thickness in Patients With Acute Heart Failure · recruiting
NCT06238609 — Neuromodulation for Prevention of Intensive Care Unit Acquired Weakness and Post Intensive Care Syndrome · NA · active not recruiting
NCT05919940 — Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) · NA · recruiting
NCT05627440 — A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure · NA · recruiting
NCT05211986 — Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. · Phase 1, PHASE2 · recruiting

Other Lance Bollinger trials

Trials by the same sponsor.

NCT05956964 — NM Balance Regulation With ULLS and Loss of Sleep · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06631053 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lance Bollinger
Last refreshed: 24 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06631053.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing